Induction of tumor-specific cytotoxicity and apoptosis by doxorubicin

Anticancer Research

Volumn 25, Issue 2 A, 2005, Pages 887-893

  Suzuki, Fumika ^a   Hashimoto, Ken ^a   Kikuchi, Hirotaka ^a   Nishikawa, Hirofumi ^a   Matsumoto, Hisatoshi ^a   Shimada, Jun ^a   Kawase, Masami ^b   Sunaga, Katsuyoshi ^b   Tsuda, Tadashi ^b   Satoh, Kazue ^c   Sakagami, Hiroshi ^a  

^a MEIKAI UNIVERSITY SCHOOL OF DENTISTRY   (Japan)

^b JOSAI UNIVERSITY   (Japan)

^c SHOWA UNIVERSITY   (Japan)

Author keywords

Apoptosis; DNA fragmentation; Doxorubicin; Mdr1; Tumor specificity

Indexed keywords

1,1 DIPHENYL 2 PICRYLHYDRAZYL; 5,5 DIMETHYL 1 PYRROLINE 1 OXIDE; ANTHRACYCLINE ANTIBIOTIC AGENT; CASPASE 3; CASPASE 8; CASPASE 9; DNA FRAGMENT; DOXORUBICIN; MULTIDRUG RESISTANCE PROTEIN 1; NITRIC OXIDE; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; SCAVENGER;

APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL STRAIN HL 60; CYTOTOXICITY; ENZYME ACTIVATION; FIBROBLAST; GINGIVA; HUMAN; HUMAN CELL; IMMUNOMODULATION; PERIODONTAL LIGAMENT; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; WESTERN BLOTTING;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DOXORUBICIN; ELECTRON SPIN RESONANCE SPECTROSCOPY; FREE RADICAL SCAVENGERS; HL-60 CELLS; HUMANS; MOUTH NEOPLASMS; SUPEROXIDES;

EID: 20244389731     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Arcamone F, Franceschi G and Penco S: Adriamycin (14-hydroxydaunomycin), a novel antitumor antibiotic. Tetrahedron Lett 1007, 1969.
2. Razek AA: A comparative study of daunomycin (D) and adriamycin (A). (abstract) Proc Am Assoc Cancer Res 12: 20, 1971.
3. Arena E, d'Alessadnro N, Dusonchet L, Gebbia N, Gerbasi F, Palazzoadriano M, Raineri A, Rausa L and Tubaro E: Analysis of the pharmacokinetic characteristics, pharmacological and chemotherapeutic activity of 14-hydroxy-daunomycin (adriamycin), a new drug endowed with an antitumor activity? Arzneim.-Forsch (Drug Res) 21: 1258-1263, 1971.
4. Mihich E and Ehrke MJ: Immunomodulation effects of anticancer drugs: the example of adriamycin. Transplant Proc 16: 499-501, 1984.
5. Simpkins EH, Pearlman LF and Thompson LM: Effects of adriamycin on supercoiled DNA and calf thymus nucleosomes studied with fluorescent probes. Cancer Res 44: 613-618, 1984.
6. Tritton TR and Yee G: The anticancer agent adriamycin can be actively cytotoxic without entering cells. Science 217: 248, 1982.
7. Youngman RJ and Elstner EF: On the interaction of adriamycin with DNA: investigation of spectral changes. Arch Biochem Biophys 231: 424-429, 1984.
8. Pavone-Macaluso M, Battista Ingargiola G, Tripi M and Lamartina M: Intravestical instillation of adriamycin in treatment of bladder carcinoma. Urology 23 (Suppl): 40-47, 1984.
9. Chang AY, Putt M, Pandya K, Harris J, Gelman R, Tormey DC and Falkson G: Induction chemotherapy of dibromodulcitol, adriamycin (R), vincristin, tamoxifen, and haloestin (R) with methotrexate in metastatic breast cancer: An Eastern Cooperative Oncology Group Study (E1181). Am J Clin Oncol 21: 99-104, 1998.
10. Scher H, Yagoda A, Watson RC, Serber M and Whitmore W: Phase II trail of doxorubicin in bidimensionally measurable prostatic adenocarcinoma. J Urol 131: 1099-1102, 1984.
11. Sakagami H, Satoh K, Ohata H, Takahashi H, Yoshida H, Iida M, Kuribayashi N, Sakagami T, Momose K and Takeda M: Relationship between ascorbyl radical intensity and apoptosis-inducing activity. Anticancer Res 16: 2635-2644, 1996.
12. Sakagami H, Satoh K, Hatano T, Yoshida T and Okuda T: Possible role of radical intensity and oxidation potential for gallic acid-induced apoptosis. Anticancer Res 17: 377-380, 1997.
13. Sakagami H, Satoh K, Hakeda Y and Kumegawa M: Apoptosis-inducing activity of vitamin C and vitamin K. Cell Mol Biol 46: 129-143, 2000.
14. Heyflick L: The limited in vitro lifetime of human diploid cell strains. Exp Cell Res 37: 614-636, 1965.
15. Yanagisawa-Shiota F, Sakagami H, Kuribayashi N, Iida M, Sakagami T and Takeda M: Endonuclease activity and induction of DNA fragmentation in human myelogenous leukemic cell lines. Anticancer Res 15: 259-266, 1995.
16. Pfrunder A, Gutmann H, Beglinger C and Drewe J: Gene expression of CYP3A4, ABC-transporters (MDR1 and MRP1-MRP5) and hPXR in three different human colon carcinoma cell lines. J Pharm Pharmacol 55: 59-66, 2003.
17. Miyamoto M, Hashimoto K, Minagawa K, Satoh K, Komatsu N, Fujimaki M, Nakashima H, Yokote Y, Akahane K, Gupta M, Sarma DNK, Mitra SK and Sakagami H: Effect of polyherbal formula on NO production by LPS-stimulated mouse macrophage-like cells. Anticancer Res 22: 3293-3302, 2002.
18. Noda Y, Mori A and Packer L: Gliclazide scavenges hydroxyl, superoxide and nitric oxide radicals. An ESR study. Res Commun Mol Pathol Pharmacol 96: 115-124, 1997.
19. Satoh K, Ida Y, Tomioka M, Shiohara K, Sakagami H and Fujisawa S: Interaction between antioxidants and hydroquinone/bisphenol A: Anticancer Res 19: 5457-5462, 1999.
20. Kawase M, Sakagami H, Hashimoto K, Tani S, Hauer H and Chatterjee SS: Structure-cytotoxic activity relationships of simple hydroxylated coumarins. Anticancer Res 23: 3243-3246, 2003.
21. Kawase M, Sakagami H, Furuya K, Kikuchi H, Nishikawa H, Motohashi N, Morimoto Y, Varga A and Molnar J: Cell death-inducing activity of opiates in human oral tumor cell lines. Anticancer Res 22: 211-214, 2001.
22. Nakayachi T, Yasumoto E, Nakano K, Morshed SRM, Hashimoto K, Kikuchi H, Nishikawa H, Kawase M and Sakagami H: Structure-activity relationships of α,β-unsaturated ketones as assessed by their cytotoxicity against oral tumor cells. Anticancer Res 24: 737-742, 2004.
23. Yasumoto E, Nakano K, Nakayachi T, Morshed SRM, Hashimoto K, Kikuchi H, Nishikawa H, Kawase M and Sakagami H: Cytotoxic activity of deferiprone, maltol and related hydroxyketones against human tumor cell lines. Anticancer Res 24: 755-762, 2004.
24. Nakano K, Nakayachi T, Yasumoto E, Morshed SRM, Hashimoto K, Kikuchi H, Nishikawa H, Sugiyama K, Amano O, Kawase M and Sakagami H: Induction of apoptosis by β-diketones in human tumor cells. Anticancer Res 24: 711-718, 2004.
25. Momoi K, Sugita Y, Ishihara M, Satoh K, Kikuchi H, Hashimoto K, Yokoe I, Nishikawa H, Fujisawa S and Sakagami H: Cytotoxic activity of styrylchromones against human tumor cell lines. In Vivo 19: 157-163, 2005.
26. Finkel E: Does cancer therapy trigger cell suicide? Science 286: 2256-2258, 1999.
27. Lee C-Y and Baehrecke EH: Steroid regulation of autophagic programmed cell death during development. Development 128: 1443-1455, 2001.
28. Yu L, Alva A, Su H, Dutt P, Freundt E, Welsh S, Baehrecke EH and Lenardo MJ: Regulation of an ATG7-beclin 1 program of autophagic cell death by caspase-8. Science 304: 1500-1502, 2004.
29. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M and Brinkmann U: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97: 3273-3478, 2000.
30. Grassilli E, Ballabeni A, Maellaro E, Bell BD and Helin K: Loss of MYC confers resistance to doxorubicin-induced apoptosis by preventing the activation of multiple serine protease- and caspase-mediated pathways. J Biol Chem 279: 21318-21326, 2004.
31. Lefrak EA, Pitha J, Rosenheim S and Gottlieb JA: A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 32: 302-314, 1973.